Cargando…

BAY 61-3606, CDKi, and sodium butyrate treatments alter gene expression in human vestibular schwannomas and cause cell death in vitro

BACKGROUND: Disrupted kinase and signaling pathways are found in many human cancers and they are implicated in carcinogenesis. Therefore, kinases have been important targets for the development of cancer therapeutics. Human vestibular schwannomas (VS) are the third most common intracranial tumours w...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitra, Rohan, Bhagavatula, Indira Devi, Gope, Rajalakshmi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3530378/
https://www.ncbi.nlm.nih.gov/pubmed/23304241
http://dx.doi.org/10.3332/ecancer.2012.285
_version_ 1782253999685107712
author Mitra, Rohan
Bhagavatula, Indira Devi
Gope, Rajalakshmi
author_facet Mitra, Rohan
Bhagavatula, Indira Devi
Gope, Rajalakshmi
author_sort Mitra, Rohan
collection PubMed
description BACKGROUND: Disrupted kinase and signaling pathways are found in many human cancers and they are implicated in carcinogenesis. Therefore, kinases have been important targets for the development of cancer therapeutics. Human vestibular schwannomas (VS) are the third most common intracranial tumours which occur in the vestibular branch of VIII(th ) cranial nerve. Sodium butyrate (Na-Bu) is a potent histone deacetylase inhibitor (HDACi) and with therapeutic efficacy. Spleen tyrosine kinase (Syk) has been implicated in many immunological consequences and is a putative target for cancer treatment. AIMS AND OBJECTIVES: The present study was undertaken in order to evaluate the effect Na-Bu, 2,4-Diamino-5-oxo-pyrimidine hydrochloride (CDKi), a broad spectrum kinase inhibitor and BAY 61-3606 (Syk inhibitor) on the survival of VS tumour tissues in vitro and their possible effects on cell survival/death and levels of a few key proteins in the treated cells as compared to the untreated cells. MATERIALS AND METHODS: Fresh tumour tissues were collected randomly from 16 patients with sporadic, VS tumours, minced into pieces and maintained in primary cultures. Twenty four hours later these cells were exposed to Na-Bu, BAY 61-3606 or CDKi. Forty eight hours after exposure, the tissue lysates were analysed by western blotting for expression of pRb and other proteins involved in cell survival/death. SUMMARY AND SIGNIFICANCE OF THE FINDINGS: The tissue samples used were positive for S100A protein, the maker for schwann cells confirming the VS tumour samples. The three individual treatments led to morphological change, DNA fragmentation and cell death and significantly reduced level of total and phosphorylated forms of pRb protein and drastically reduced EGF-R protein. These treatments also modulated levels of other proteins involved in cell survival/death such as PI3K, Caspase 3, TGF-β1, JNK, ASK1, Shh, NF-κB, p21(cip1/waf1). The Untreated cells had uncleaved PARP-1 protein and the treated cells had cleaved PARP-1. The results show that the observed cell death in treated cells perhaps is mediated by modulation of the levels and processing of certain key proteins. The possible development of these components as therapeutics is discussed.
format Online
Article
Text
id pubmed-3530378
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-35303782013-01-09 BAY 61-3606, CDKi, and sodium butyrate treatments alter gene expression in human vestibular schwannomas and cause cell death in vitro Mitra, Rohan Bhagavatula, Indira Devi Gope, Rajalakshmi Ecancermedicalscience Research BACKGROUND: Disrupted kinase and signaling pathways are found in many human cancers and they are implicated in carcinogenesis. Therefore, kinases have been important targets for the development of cancer therapeutics. Human vestibular schwannomas (VS) are the third most common intracranial tumours which occur in the vestibular branch of VIII(th ) cranial nerve. Sodium butyrate (Na-Bu) is a potent histone deacetylase inhibitor (HDACi) and with therapeutic efficacy. Spleen tyrosine kinase (Syk) has been implicated in many immunological consequences and is a putative target for cancer treatment. AIMS AND OBJECTIVES: The present study was undertaken in order to evaluate the effect Na-Bu, 2,4-Diamino-5-oxo-pyrimidine hydrochloride (CDKi), a broad spectrum kinase inhibitor and BAY 61-3606 (Syk inhibitor) on the survival of VS tumour tissues in vitro and their possible effects on cell survival/death and levels of a few key proteins in the treated cells as compared to the untreated cells. MATERIALS AND METHODS: Fresh tumour tissues were collected randomly from 16 patients with sporadic, VS tumours, minced into pieces and maintained in primary cultures. Twenty four hours later these cells were exposed to Na-Bu, BAY 61-3606 or CDKi. Forty eight hours after exposure, the tissue lysates were analysed by western blotting for expression of pRb and other proteins involved in cell survival/death. SUMMARY AND SIGNIFICANCE OF THE FINDINGS: The tissue samples used were positive for S100A protein, the maker for schwann cells confirming the VS tumour samples. The three individual treatments led to morphological change, DNA fragmentation and cell death and significantly reduced level of total and phosphorylated forms of pRb protein and drastically reduced EGF-R protein. These treatments also modulated levels of other proteins involved in cell survival/death such as PI3K, Caspase 3, TGF-β1, JNK, ASK1, Shh, NF-κB, p21(cip1/waf1). The Untreated cells had uncleaved PARP-1 protein and the treated cells had cleaved PARP-1. The results show that the observed cell death in treated cells perhaps is mediated by modulation of the levels and processing of certain key proteins. The possible development of these components as therapeutics is discussed. Cancer Intelligence 2012-12-20 /pmc/articles/PMC3530378/ /pubmed/23304241 http://dx.doi.org/10.3332/ecancer.2012.285 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Mitra, Rohan
Bhagavatula, Indira Devi
Gope, Rajalakshmi
BAY 61-3606, CDKi, and sodium butyrate treatments alter gene expression in human vestibular schwannomas and cause cell death in vitro
title BAY 61-3606, CDKi, and sodium butyrate treatments alter gene expression in human vestibular schwannomas and cause cell death in vitro
title_full BAY 61-3606, CDKi, and sodium butyrate treatments alter gene expression in human vestibular schwannomas and cause cell death in vitro
title_fullStr BAY 61-3606, CDKi, and sodium butyrate treatments alter gene expression in human vestibular schwannomas and cause cell death in vitro
title_full_unstemmed BAY 61-3606, CDKi, and sodium butyrate treatments alter gene expression in human vestibular schwannomas and cause cell death in vitro
title_short BAY 61-3606, CDKi, and sodium butyrate treatments alter gene expression in human vestibular schwannomas and cause cell death in vitro
title_sort bay 61-3606, cdki, and sodium butyrate treatments alter gene expression in human vestibular schwannomas and cause cell death in vitro
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3530378/
https://www.ncbi.nlm.nih.gov/pubmed/23304241
http://dx.doi.org/10.3332/ecancer.2012.285
work_keys_str_mv AT mitrarohan bay613606cdkiandsodiumbutyratetreatmentsaltergeneexpressioninhumanvestibularschwannomasandcausecelldeathinvitro
AT bhagavatulaindiradevi bay613606cdkiandsodiumbutyratetreatmentsaltergeneexpressioninhumanvestibularschwannomasandcausecelldeathinvitro
AT goperajalakshmi bay613606cdkiandsodiumbutyratetreatmentsaltergeneexpressioninhumanvestibularschwannomasandcausecelldeathinvitro